Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Engineering Superaffinity Antibody Dependent Cellular Cytotoxcity Receptors into iPSC-Derived NK Cells As Next-Generation Immunotherapies for Cancer

Spencer Goodman, Kenyon Lyon, Katelin Hartwig, Suping Peng, Qin Li, David Murray, Davide Bernareggi, Caryn Gonsalves, Max Schabla, Guoxin Zhang, Terri Harder, Baohu Ji, Leah Mitchell, Dan S Kaufman, Robert Hollingsworth, Huang Zhu

Blood (2023) 142 (Supplement 1): 2060.

https://doi.org/10.1182/blood-2023-181261

Published: 2023

Journal Articles

Human iPSC-Derived NK Cells with Knock-in of the BCL2 G101V Mutation Are Resistant to Venetoclax and Demonstrate Improved Anti-AML Activity In Vivo

Benjamin Goldenson, Davide Bernareggi, Jiyoung Yun, Samuel Shia, Dan S Kaufman

Blood (2023) 142 (Supplement 1): 464.

https://doi.org/10.1182/blood-2023-177527

Published: 2023

Journal Articles

A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-Shelf Cancer Immunotherapy

Davide Bernareggi, Caryn Gonsalves, Max Schabla, Alejandra Garate-Carrilo, Mohammad El-Kalay, Dan S Kaufman, Robert Hollingsworth, Huang Zhu

Blood (2022) 140 (Supplement 1): 1613–1614.

https://doi.org/10.1182/blood-2022-163871

Published: 2022

Journal Articles

Knock-in of the BCL2 G101V Mutation in Human iPSC-Derived NK Cells Generates Venetoclax Resistance and Improves Activity Against Venetoclax Resistant AML

Davide Bernareggi, Jiyoung Yun, Benjamin Goldenson, Dan S Kaufman

Blood (2022) 140 (Supplement 1): 7407–7408.

https://doi.org/10.1182/blood-2022-160203

Published: 2022